Acta Neuropathologica

, Volume 108, Issue 2, pp 121–128 | Cite as

Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer’s disease

  • Wami Marui
  • Eizo Iseki
  • Masanori Kato
  • Hiroyasu Akatsu
  • Kenji Kosaka
Regular Paper


We reclassified the pathological subtypes of dementia with Lewy bodies (DLB), based on both Lewy pathology and Alzheimer pathology, to clarify the pathological entity of DLB and the boundary between DLB and Alzheimer’s disease (AD) in autopsied cases, using both pathological and immunohistochemical methods. DLB was classified as either limbic type or neocortical type according to the degree of Lewy pathology including Lewy bodies (LB) and LB-related neurites by our staging, and was classified as pure form, common form or AD form according to the degree of Alzheimer pathology including neurofibrillary tangles (NFT) and amyloid deposits by Braak staging. These combined subtypes were lined up on a spectrum, not only with Lewy pathology but also with other DLB-related pathologies including Alzheimer pathology, neuronal loss in the substantia nigra, spongiform change in the transentorhinal cortex and LB-related neurites in the CA2–3 region. In contrast, the Lewy pathology of AD did not meet the stages of Lewy pathology in DLB, and there were scarcely any similarities in other DLB-related pathologies between AD and DLB. In addition, the Lewy pathology of AD had characteristics different from that of DLB, including the coexistence rate of LB with NFT, and the immunohistochemical and immunoelectron microscopic findings of LB and LB-related neurites. These findings suggest that DLB is a distinctive pathological entity that can be differentiated from AD, although it shows some pathological subtypes.


Dementia with Lewy bodies Alzheimer’s disease Lewy pathology α-Synuclein Pathological subtypes 



This research was supported by Grants-in-aid from the Japan Ministry of Education, Science, Sports and Culture, and from the Japan Ministry of Health, Labor and Welfare. We are grateful to Dr. T. Ishii for the generous supply of antibody.


  1. 1.
    Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y (2001) α-Synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation. Brain Res 888:287–296PubMedGoogle Scholar
  2. 2.
    Arima K, Mizutani T, Alim MA, Tonozuka-Uehara H, Izumiyama Y, Hirai S, Ueda K (2000) NACP/α-synuclein and tau constutute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies. Acta Neuropathol 100:115–121PubMedGoogle Scholar
  3. 3.
    Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol 152:879–884PubMedGoogle Scholar
  4. 4.
    Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMedGoogle Scholar
  5. 5.
    Braak H, Del Tredici K, Rüb U, Vos RAI de, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMedGoogle Scholar
  6. 6.
    Brown DF, Dababo MA, Bigio EH, Risser RC, Eagan KP, Hladik CL, White CL (1998) Neuropathologic evidence that the Lewy body variant of Alzheimer’s disease represents coexistence of Alzheimer disease and idiopathic Parkinson’s disease. J Neuropathol Exp Neurol 57:39–46Google Scholar
  7. 7.
    Del Tredici, Rüb U, Vos RAI de, Boel JRE, Braak H (2002) Where does Parkinson’s disease pathology begin in the brain? J Neuropathol Exp Neurol 61:413–426Google Scholar
  8. 8.
    Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol 10:378–384PubMedGoogle Scholar
  9. 9.
    Hansen LA, Salmon D, Galasko D, Masliah E, Katzman R, De Teresa R, Thal L, Pay MM, Hofstetter R, Klauber M, Rice V, Butters N, Alford M (1990) The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 40:1–8Google Scholar
  10. 10.
    Harding AJ, Stimson E, Henderson JM, Halliday GM (2002) Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain 125:2431–2445CrossRefPubMedGoogle Scholar
  11. 11.
    Iseki E, Odawara T, Suzuki K, Kosaka K, Akiyama H, Ikeda K (1995) A pathological study of Lewy bodies and senile changes in the amygdala in diffuse Lewy body disease. Neuropathology 15:112–116Google Scholar
  12. 12.
    Iseki E, Marui W, Akiyama H, Ueda K, Iwatsubo T (1998) Degenerative terminals of the perforant pathway are human α-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease. Neurosci Lett 258:81–84PubMedGoogle Scholar
  13. 13.
    Iseki E, Marui W, Kosaka K, Ueda K (1999) Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett 265:9–12PubMedGoogle Scholar
  14. 14.
    Iseki E, Marui W, Kosaka K, Kato M, Yamamoto T, Ueda K (1999) Clinicopathological multiplicity of dementia with Lewy bodies. Neuropathology 19:386–394CrossRefGoogle Scholar
  15. 15.
    Jellinger KA (2003) α-Synuclein pathology in Parkinson’s disease and Alzheimer’s disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol 106:191–201CrossRefPubMedGoogle Scholar
  16. 16.
    Katsuse O, Iseki E, Marui W, Kosaka K (2003) Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci 211:29–35PubMedGoogle Scholar
  17. 17.
    Kosaka K (1978) Lewy bodies in cerebral cortex. Report of three cases. Acta Neuropathol (Berl) 42:127–134Google Scholar
  18. 18.
    Kosaka K (1990) Diffuse Lewy body disease in Japan. J Neurol 237:197–204PubMedGoogle Scholar
  19. 19.
    Kosaka K, Iseki E, Odawara T, Yamamoto T (1996) Cerebral type of Lewy body disease. Neuropathology 16:32–35Google Scholar
  20. 20.
    Leigh PN, Probst A, Dale GE, Power DP, Brion JP, Dodson A, Anderson BH (1989) New aspect of the pathology of neurodegenerative disorders as revealed by ubiquitin antibodies. Acta Neuropathol 79:61–72PubMedGoogle Scholar
  21. 21.
    Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O’Connel B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ (1998) Lewy bodies contain alteredα-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365–1370PubMedGoogle Scholar
  22. 22.
    Marui W, Iseki E, Ueda K, Kosaka K (2000) Occurrence of human α-synuclein-immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer’s disease. J Neurol Sci 174:81–84PubMedGoogle Scholar
  23. 23.
    Marui W, Iseki E, Nakai T, Miura S, Kato M, Ueda K, Kosaka K (2002) Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 195:153–159CrossRefPubMedGoogle Scholar
  24. 24.
    McKeith IG, Glasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Millar BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, Vos RAI de, Willcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB workshop. Neurology 47:1113–1124PubMedGoogle Scholar
  25. 25.
    Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Belle G van, Berg L (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standarization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMedGoogle Scholar
  26. 26.
    Parkkinen L, Soininen H, Alafuzoff I (2003) Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer’s disease. J Neuropathol Exp Neurol 62:363–367Google Scholar
  27. 27.
    Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK (1990) Senile dementia of Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 95:119–139PubMedGoogle Scholar
  28. 28.
    Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) α-Synuclein in Lewy bodies. Nature 388:839–840PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Wami Marui
    • 1
  • Eizo Iseki
    • 1
  • Masanori Kato
    • 2
  • Hiroyasu Akatsu
    • 3
  • Kenji Kosaka
    • 3
  1. 1.Department of PsychiatryYokohama City University School of MedicineYokohamaJapan
  2. 2.Soga HospitalOdawaraJapan
  3. 3.Fukushimura HospitalToyohashiJapan

Personalised recommendations